
Venus Concept VERO
Quarterly report 2025-Q3
added 11-13-2025
Venus Concept Accounts Payables 2011-2026 | VERO
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Venus Concept
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.48 M | 9.04 M | 8.03 M | 8.42 M | 6.32 M | 9.4 M | 3.82 M | 2.04 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.4 M | 2.04 M | 6.69 M |
Quarterly Accounts Payables Venus Concept
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.11 M | 5.85 M | 7.37 M | 6.48 M | 7.12 M | 7.19 M | 7.79 M | 9.04 M | 7.12 M | 8.29 M | 7.51 M | 8.03 M | 6.09 M | 4.18 M | 4.79 M | 4.91 M | 4.75 M | 5.68 M | 6.14 M | 6.32 M | 6.32 M | 6.32 M | 6.32 M | 9.4 M | 5.23 M | 5.9 M | 4.19 M | 3.82 M | 3.95 M | 3.82 M | 3.82 M | 2.04 M | 2.04 M | 2.04 M | 2.04 M | 1.74 M | 1.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.4 M | 1.74 M | 5.47 M |
Accounts Payables of other stocks in the Medical devices industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
2.76 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
1.21 M | - | 3.58 % | $ 2.21 M | ||
|
Alphatec Holdings
ATEC
|
40.9 M | $ 13.93 | 5.85 % | $ 2.09 B | ||
|
Apollo Endosurgery
APEN
|
7.42 M | - | - | $ 475 M | ||
|
AxoGen
AXGN
|
2.89 M | $ 32.5 | -8.14 % | $ 1.5 B | ||
|
Avinger
AVGR
|
777 K | - | -20.74 % | $ 369 K | ||
|
Aziyo Biologics
AZYO
|
2.28 M | - | 1.37 % | $ 20.5 M | ||
|
Bio-Rad Laboratories
BIO
|
122 M | $ 268.7 | - | $ 7.58 B | ||
|
BIOLASE
BIOL
|
6.06 M | - | -13.19 % | $ 166 K | ||
|
Cognyte Software Ltd.
CGNT
|
25.2 M | $ 6.39 | 0.79 % | $ 459 M | ||
|
Axonics Modulation Technologies
AXNX
|
9.07 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
2.71 M | $ 3.54 | -0.84 % | $ 123 M | ||
|
Conformis
CFMS
|
4.16 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
1.34 M | $ 14.55 | -1.42 % | $ 393 M | ||
|
EDAP TMS S.A.
EDAP
|
5.71 M | $ 4.47 | -1.11 % | $ 167 M | ||
|
Cardiovascular Systems
CSII
|
14.4 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
234 M | $ 39.77 | 0.53 % | $ 5.93 K | ||
|
Boston Scientific Corporation
BSX
|
1.14 B | $ 75.15 | - | $ 111 B | ||
|
Dynatronics Corporation
DYNT
|
3.4 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
2.67 M | $ 23.15 | -5.16 % | $ 196 M | ||
|
CONMED Corporation
CNMD
|
93.6 M | $ 46.06 | - | $ 1.43 B | ||
|
Second Sight Medical Products
EYES
|
817 K | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
1.47 M | - | -0.57 % | $ 7.12 M | ||
|
Cutera
CUTR
|
19.8 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
961 K | $ 9.95 | 2.16 % | $ 284 M | ||
|
LivaNova PLC
LIVN
|
69.7 M | $ 69.05 | 1.02 % | $ 3.75 B | ||
|
Eargo
EAR
|
6.5 M | - | - | $ 10.2 M | ||
|
InMode Ltd.
INMD
|
17.9 M | $ 13.98 | -1.55 % | $ 904 M | ||
|
IRadimed Corporation
IRMD
|
1.9 M | $ 99.09 | -1.92 % | $ 1.26 B | ||
|
Establishment Labs Holdings
ESTA
|
44.8 M | $ 79.67 | 6.28 % | $ 2.24 B | ||
|
Invacare Corporation
IVC
|
105 M | - | - | $ 24.7 M | ||
|
FONAR Corporation
FONR
|
1.55 M | $ 18.57 | -0.11 % | $ 122 M | ||
|
Pulmonx Corporation
LUNG
|
3.83 M | $ 1.51 | 2.03 % | $ 59.1 M | ||
|
Globus Medical
GMED
|
98.9 M | $ 91.88 | - | $ 12.4 B | ||
|
Helius Medical Technologies
HSDT
|
531 K | $ 1.85 | -1.6 % | $ 1.12 M | ||
|
Myomo
MYO
|
570 K | $ 0.65 | -5.24 % | $ 4.58 M | ||
|
Medtronic PLC
MDT
|
2.45 B | $ 96.75 | - | $ 124 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
82.5 M | $ 11.53 | -1.96 % | $ 888 M |